This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Medtronic (MDT) Beats on Q3 Earnings, Reiterates FY18 View
by Zacks Equity Research
Medtronic (MDT) rides high on strength in all business segments in Q3.
The Zacks Analyst Blog Highlights: Boeing, PetMed, Micron, Healthcare and RH
by Tirthankar Chakraborty
The Zacks Analyst Blog Highlights: Boeing, PetMed, Micron, Healthcare and RH
Buy These 4 Retail Growth Stocks to Brave Soft Sales Woes
by Zacks Equity Research
Looking superficially, the numbers do raise concerns but a meticulous approach may help alleviate fears. Analysts cited the slump in retail sales as a temporary hitch after a sturdy holiday season.
Inflation Scares Overblown! Grab 5 Growth Stocks Now
by Tirthankar Chakraborty
The rise in consumer price index (CPI), especially on a year-on-year basis, remained sluggish, while the recent wage growth was primarily due to seasonal factors that are not likely to last long.
TripAdvisor (TRIP) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
TripAdvisor's (TRIP) fourth-quarter results were impacted by a weak performance in the Hotel business. Also, increasing marketing investments continue to be a concern.
Applied Materials (AMAT) Beats on Q1 Earnings and Revenues
by Zacks Equity Research
Applied Materials (AMAT) delivers strong fiscal first-quarter results on the back of demand for chips used in electronic items, differentiated products, new technologies and innovation strategy.
Hone in on DuPont Analysis & Pick 5 Top Stocks
by Zacks Equity Research
Do you have more faith in DuPont analysis than simple ROE calculation? Bet on these five stocks.
Chemed (CHE) Beats on Q4 Earnings & Revenues, Issues View
by Zacks Equity Research
Chemed (CHE) rides on strong contributions from the Roto-Rooter and VITAS businesses in Q4.
GNC Holdings (GNC) Tops Q4 Earnings, Lags Revenue Estimates
by Zacks Equity Research
Despite sluggish performance by manufacturing/wholesale segments, GNC Holdings (GNC) witnesses revenue growth in Q4.
DaVita (DVA) Beats Q4 Earnings Estimates, Misses Revenues
by Zacks Equity Research
Impressive results from Kidney Care business drove DaVita (DVA) in Q4.
Amkor Technology (AMKR) Beats on Q4 Earnings, Revenues
by Zacks Equity Research
Amkor Technology (AMKR) delivers strong fourth-quarter earnings aided by robust growth in all end markets, primarily auto and mobile communication end markets.
Luminex (LMNX) Beats on Q4 Earnings & Revenues, Issues View
by Zacks Equity Research
Luminex's (LMNX) favorable tidings at the regulatory front in Q4 buoy optimism.
Bruker (BRKR) Beats on Q4 Earnings & Revenues, Issues View
by Zacks Equity Research
Bruker (BRKR) registers organic revenue growth on strength in NANO and BEST platforms in Q4.
Hologic (HOLX) Q1 Earnings & Revenues Top, Margins Down
by Zacks Equity Research
Solid growth at Hologic's (HOLX) Molecular Diagnostics, Breast Health and international business drives the top line in Q1.
Surmodics (SRDX) Beats on Earnings in Q1, Guidance Solid
by Zacks Equity Research
Solid performance in the In Vitro Diagnostics segment drives Surmodics (SRDX) in first-quarter fiscal 2018.
Expedia (EXPE) Q4 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
Expedia's (EXPE) fourth-quarter results hurt by continuing investments in accelerated supply acquisition and cloud migration.
CVS Health (CVS) Q4 Earnings Beat Estimates, '18 View Upbeat
by Zacks Equity Research
A strong Pharmacy Services segment, benefiting from the upside in the specialty services Drives CVS Health's (CVS) topline in Q4.
Cardinal Health (CAH) Beats on Q2 Earnings, Raises '18 View
by Zacks Equity Research
Solid performance at the Medical Segment drove Cardinal Health (CAH) in Q2.
Nielsen (NLSN) Q4 Earnings Up Y/Y, Revenues Match Estimates
by Zacks Equity Research
Nielsen (NLSN) delivers strong fourth-quarter profits driven by strength in Watch segment. Weakness in the U.S. Buy segment continues to be a concern.
Cardiovascular Systems (CSII) Q2 Earnings Top, Revenues Lag
by Zacks Equity Research
Cardiovascular Systems (CSII) witnesses year-over-year increase in Q2 revenues on strength in both the segments.
STERIS (STE) Q3 Earnings Beat & Revenues Miss, Margins Up
by Zacks Equity Research
STERIS (STE) witnesses year-over-year rise in Q3 revenues on favorable underlying market trends along with new product and service offerings.
The Zacks Analyst Blog Highlights: Capital City Bank, HCA, MSCI, PetMed and Saia
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Capital City Bank, HCA, MSCI, PetMed and Saia
Cerner (CERN) Misses Q4 Earnings Estimates, Bookings Soar
by Zacks Equity Research
Despite a decline in earnings year over year, all-time high bookings drive Cerner's (CERN) top line in Q4.
5 Top Stocks to Buy During This Bull & Bear Tug-of-War
by Tirthankar Chakraborty
While bullish investors show optimism on corporate earnings and prospects of tax cut, those with a bearish view fear that the Fed's embarking on a quicker route to interest rate hikes might derail the record bull run.
Haemonetics' (HAE) Q3 Earnings Top Estimates, EPS View Up
by Zacks Equity Research
Continued momentum in new business generation and geographical expansions drive Haemonetics (HAE) in the third quarter.